GlassScriptPhysician profile
Alison L Bailey
NPI 1992715502
$27,567.08
in general payments reported to CMS, 2019-2025
50 companies · $12K in 2025
The $12K reported for 2025 was more than what 78% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,935 · 2020: $3,461 · 2021: $1,912 · 2022: $775 · 2023: $1,803 · 2024: $5,173 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,640 · Food and Beverage: $4,323 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,588 · Travel and Lodging: $1,773 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,640.00 |
| Food and Beverage | $4,322.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,588.00 |
| Travel and Lodging | $1,772.79 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,120.96 | 2020-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $5,495.38 | 2021-2025 | Linq II, Cobalt Dr Mri Surescan |
| Ge Healthcare | $3,077.00 | 2020-2021 | |
| Csl Behring | $2,302.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,396.41 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $767.62 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Pfizer INC. | $606.03 | 2019-2025 | |
| Abbott Laboratories | $565.57 | 2019-2025 | Cardiomems, Amplatzer Amulet, Amplatzer Talisman |
| Boston Scientific Corporation | $413.97 | 2019-2024 | Watchman Flx, Wavewriter Alpha Prime 16, Watchman Access System |
| Janssen Pharmaceuticals, INC | $399.24 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $338.06 | 2021-2025 | Winrevair, Verquvo |
| Amgen INC. | $289.86 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.46 | 2020-2024 | Lifevest |
| Novo Nordisk INC | $269.92 | 2022-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.61 | 2021-2025 | Jardiance |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.